Literature DB >> 23431481

Lipoprotein X in a patient with cholestasis and hypertriglyceridaemia.

Karolina M Stepien1, Hrushikesh Divyateja, Farhan Ahmed, Peter Prinsloo, Pankaj Gupta.   

Abstract

Hypertriglyceridaemia is an established cause of acute pancreatitis and responds to insulin therapy in addition to lipid lowering medication. We report a case of severe hypertriglycaeridemia of 149 mmol/L in a 36-year-old man with type 2 diabetes who presented to the surgical ward with abdominal pain due to pancreatitis and developed acute cholestasis, jaundice and eruptive xanthomata. His triglycerides improved to 3.8 mmol/L with sliding scale insulin within two weeks of in-hospital stay. However, his total cholesterol remained raised at 23.7 mmol/L. The lipoprotein electrophoresis confirmed the presence of lipoprotein X associated with bile obstruction, which contributed to an increase in total cholesterol. The total cholesterol normalized on improvement of his cholestasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23431481     DOI: 10.1258/acb.2012.012148

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  2 in total

1.  Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia.

Authors:  Agnieszka Ćwiklińska; Agnieszka Mickiewicz; Robert Kowalski; Barbara Kortas-Stempak; Agnieszka Kuchta; Krzysztof Mucha; Michał Makowiecki; Anna Gliwińska; Krzysztof Lewandowski; Leszek Pączek; Marcin Fijałkowski; Marcin Gruchała; Maciej Jankowski
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

2.  Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.

Authors:  Shimpi Bedi; Erwin Garcia; Elias J Jeyarajah; Irina Shalaurova; Maria Camila Perez-Matos; Z Gordon Jiang; Robin P F Dullaart; Steven P Matyus; William J Kirk; James D Otvos; W Sean Davidson; Margery A Connelly
Journal:  J Clin Med       Date:  2020-09-10       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.